Benjamin L Palleiko Kal Vista Pharmaceuticals, Inc. (KALV) insider trading activity

Benjamin L Palleiko is CHIEF EXECUTIVE OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 266,598 shares of KALV, which is worth approximately $2.39 Million. The most recent transaction as insider was on Nov 18, 2024, when has been sold 14,400 shares (Common Stock) at a price of $9.26 per share, resulting in proceeds of $133,344. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 267K

9.93% 3M change

137.1% 12M change

Total Value Held $2.39 Million

Benjamin L Palleiko Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 18 2024	SELL Open market or private sale	$133,344 $9.26 p/Share	14,400 Reduced 5.12%	266,598 Common Stock
Nov 17 2024	BUY Exercise of conversion of derivative security	-	30,198 Added 9.7%	280,998 Common Stock
Sep 09 2024	SELL Open market or private sale	$89,620 $12.19 p/Share	7,352 Reduced 2.85%	250,800 Common Stock
Sep 06 2024	BUY Exercise of conversion of derivative security	-	15,625 Added 5.71%	258,152 Common Stock
Aug 19 2024	SELL Open market or private sale	$170,722 $12.01 p/Share	14,215 Reduced 5.54%	242,527 Common Stock
Aug 17 2024	BUY Exercise of conversion of derivative security	-	30,195 Added 10.52%	256,742 Common Stock
Jun 07 2024	SELL Open market or private sale	$86,071 $11.53 p/Share	7,465 Reduced 3.22%	224,547 Common Stock
Jun 06 2024	BUY Exercise of conversion of derivative security	-	15,625 Added 6.31%	232,012 Common Stock
May 20 2024	SELL Open market or private sale	$258,237 $11.76 p/Share	21,959 Reduced 9.21%	216,387 Common Stock
May 17 2024	BUY Exercise of conversion of derivative security	-	51,031 Added 17.63%	238,346 Common Stock
Feb 20 2024	SELL Open market or private sale	$321,736 $14.11 p/Share	22,802 Reduced 10.85%	187,315 Common Stock
Feb 17 2024	BUY Exercise of conversion of derivative security	-	51,029 Added 19.54%	210,117 Common Stock
Feb 14 2024	SELL Open market or private sale	$613,233 $15.01 p/Share	40,855 Reduced 20.43%	159,088 Common Stock
Feb 11 2024	BUY Grant, award, or other acquisition	-	87,500 Added 30.44%	199,943 Common Stock
Nov 20 2023	SELL Open market or private sale	$107,055 $8.23 p/Share	13,008 Reduced 10.37%	112,443 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	30,197 Added 19.4%	125,451 Common Stock
Aug 18 2023	SELL Open market or private sale	$140,208 $10.73 p/Share	13,067 Reduced 12.06%	95,254 Common Stock
Aug 17 2023	BUY Exercise of conversion of derivative security	-	30,195 Added 21.8%	108,321 Common Stock
May 18 2023	SELL Open market or private sale	$40,935 $10.14 p/Share	4,037 Reduced 4.91%	78,126 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	9,364 Added 10.23%	82,163 Common Stock
Feb 17 2023	SELL Open market or private sale	$37,947 $7.66 p/Share	4,954 Reduced 6.37%	72,799 Common Stock
Feb 17 2023	BUY Exercise of conversion of derivative security	-	9,363 Added 10.75%	77,753 Common Stock
Nov 18 2022	SELL Open market or private sale	$3,927 $5.44 p/Share	722 Reduced 1.04%	68,390 Common Stock
Nov 17 2022	BUY Exercise of conversion of derivative security	-	2,419 Added 3.38%	69,112 Common Stock
Aug 17 2022	SELL Open market or private sale	$10,846 $14.96 p/Share	725 Reduced 1.08%	66,693 Common Stock

BLP

Benjamin L Palleiko

CHIEF EXECUTIVE OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Value

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

Operation

Value

Type

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV

Account